PD-L1

July 16, 2020July 16, 2020

Tecentriq Combo Produces Disappointing Results in Advanced Ovarian Cancer Trial

News

The addition of Tecentriq (atezolizumab) to first-line treatment with Avastin (bevacizumab) and chemotherapy does not significantly extend survival without disease worsening in people with newly-diagnosed advanced ovarian cancer, a recent ... Read more

February 14, 2020February 14, 2020

Checkpoint Inhibitor Combination Well-tolerated, Effective in Ovarian Cancer Patients, Phase 1b Trial Shows

News

A combination of two checkpoint inhibitor therapies, magrolimab (Hu5F9-G4) and Bavencio (avelumab), has an acceptable safety profile, is well-tolerated, and stabilizes disease in more than half of heavily-treated ovarian cancer ... Read more

June 7, 2019

Immune Checkpoint Molecules Have Prognostic Value in Ovarian Cancer, Study Reports

News

The immune checkpoint molecules PD-L1 and TIM-3 have prognostic value in people with ovarian cancer who have not yet received chemotherapy. But while low levels of TIM-3 were linked to ... Read more

January 19, 2018January 19, 2018

Agreement Reached to Test Hu5F9-G4 and Avelumab Combo for Ovarian Cancer

News

A new Phase 1b clinical trial testing a combination treatment of Hu5F9-G4 with avelumab in patients with ovarian cancer is set to begin as part of an agreement between Forty Seven and Merck KGaA, Darmstadt, ... Read more

September 19, 2016September 19, 2016

New Alternative Found for Boosting Ovarian Cancer Immune Responses

News

Researchers at The Wistar Institute in Philadelphia have identified an experimental drug that shows great promise in halting ovarian cancer progression. The treatment, which is currently in clinical trials for a number ... Read more

July 18, 2016July 18, 2016

Immunotherapy Following Chemotherapy May Benefit Metastatic Ovarian Cancer Patients

News

Women with metastatic ovarian cancer treated with chemotherapy prior to surgery have higher levels of specific immune cells with the ability to attack tumor cells. These findings suggest that immunotherapy designed to remove the breaks ... Read more